Recurrent hyperkalaemia management and use of renin–angiotensin–aldosterone system inhibitors: a European multi-national targeted chart review

Recurrent hyperkalaemia management and use of renin–angiotensin–aldosterone system inhibitors: a European multi-national targeted chart review Patrick Rossignol, Luis M. Ruilope, Adamasco Cupisti, Markus Ketteler, David C. Wheeler, Marc Pignot, Georgiana Cornea, Thierry Schulmann and Lars H. Lund Université de Lorraine, Inserm, Centre d’Investigations Cliniques-Plurithématique 14-33, Inserm U116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France, Hypertension Unit, Instituto de Investigación imas12, Hospital Universitario, Madrid, Spain, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus, Stuttgart, Germany, University of Split School of Medicine, Split, Croatia, Clinical Effectiveness Group, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK, Kantar Health GmbH, Real World Research & Value, Munich, Germany, Vifor Pharma Group, Glattbrugg, Switzerland, Department of Medicine, Karolinska Institutet, Stockholm, Sweden and Karolinska University Hospital, Heart and Vascular Theme, Stockholm, Sweden